邓金凤

[摘要] 目的 探讨芳香化酶抑制剂在妇科内分泌疾病治疗中的应用价值。 方法 选取2010年8月～2012年8月在本院治疗的妇科内分泌患者90例，分别给予依西美坦（n=36）、阿那曲唑（n=28）和来曲唑（n=26）治疗，观察芳香化酶抑制剂的疗效、3组患者血清雌二醇（E2）抑制情况及不良反应发生情况。 结果 依西美坦组、阿那曲唑组和来曲唑组的治疗总有效率分别为94.44%、92.86%和92.31%，差异无统计学意义（P>0.05）。治疗后3组患者血清E2水平明显下降，与治疗前比较差异有统计学意义（P<0.05）；依西美坦组患者的血清E2抑制率及有效抑制率优于其他两组（P<0.05）。3组均未出现严重不良反应；在体重增加上来曲唑组尤为显著（P<0.05）。 结论 芳香化酶抑制剂可有效治疗妇科内分泌疾病，且药物耐受性好。

[关键词] 芳香化酶抑制剂；内分泌疾病；血清雌二醇；应用价值

[中图分类号] R711 [文献标识码] A [文章编号] 1674-4721（2014）09（a）-0075-03

Effect analysis of aromatase inhibitor treatment of gynecologic endocrine diseases

DENG Jin-feng

Department of Obstetrics And Gynecology，the Second Hospital of Nanchang City，Nanchang 330002，China

[Abstract] Objective To explore the application value of aromatase inhibitor in gynecologic endocrine diseases. Methods 90 patients with gynecologic endocrine diseases treated in our hospital from August 2010 to August 2012 were selected and respectively for exemestane （n=36），anastrozole （n=28） and letrozole （n=26） treatment，the curative effect of aromatase inhibitors，three groups of patients with serum estradiol inhibition condition and adverse reactions occur were observed. Results The total effective rate was 94.44%，92.86% and 92.31% respectively in exemestane group，anastrozole group and letrozole group，there was no statistically significant difference （P>0.05）.The serum E2 level in three groups of patients were significantly decreased after treatment，the difference was statistically significant compared with before treatment （P<0.05）.The serum E2 inhibition rate and efficient inhibition in exemestane group patients were better than the other two groups （P<0.05）.No serious adverse reaction occurred in 3 groups，on weight gain letrozole group was significant （P<0.05）. Conclusion Aromatase inhibitors can effectively treat gynecological endocrine diseases，and drug tolerance.

[Key words] Aromatase inhibitors；Endocrine diseases；Serum estradiol；Application value

妇科内分泌疾病极为常见，月经不调、痛经、子宫内膜异位等均属此病，一些乳腺疾病，如乳腺增生、乳房胀痛、乳腺癌等也与内分泌失调相关；由于此病发生范围广、发生易，导致众多女性患者饱受身心痛苦，严重影响生活质量。第三代芳香化酶抑制剂（aromatase inhibitiors，AIs）如阿那曲唑、依西美坦、来曲唑等，可抑制雌性激素形成，促进排卵，在治疗子宫内膜异位症、子宫肌瘤、乳腺癌等妇科疾病中具有较高的应用价值。鉴于此，本院采用AIs治疗妇科内分泌患者，取得良好效果。

1 资料与方法

1.1 一般资料

选取2010年8月～2012年8月在本院接受治疗的妇科内分泌患者90例，年龄21～52岁，平均（40.1±3.2）岁；其中乳腺癌38例（绝经后晚期乳腺癌33例），子宫肌瘤22例，子宫内膜异位症20例，多囊卵巢综合征10例。根据用药方式将所有患者分为依西美坦组（n=36）、阿那曲唑组（n=28）和来曲唑组（n=26），3组的年龄、病情、治疗前血清雌二醇（E2）水平等一般资料差异无统计学意义（P>0.05），具有可比性。